Search alternatives:
largest decrease » largest decreases (Expand Search), marked decrease (Expand Search)
linear decrease » linear increase (Expand Search)
larger decrease » marked decrease (Expand Search)
mean decrease » a decrease (Expand Search)
largest decrease » largest decreases (Expand Search), marked decrease (Expand Search)
linear decrease » linear increase (Expand Search)
larger decrease » marked decrease (Expand Search)
mean decrease » a decrease (Expand Search)
-
13201
Acceptance of the HPV vaccine.
Published 2024“…After adjustment for other factors, it was found that higher age was associated with a decreased acceptance (AOR: 0.92; 95% CI: 0.89–0.95). …”
-
13202
Cues to the action question.
Published 2024“…After adjustment for other factors, it was found that higher age was associated with a decreased acceptance (AOR: 0.92; 95% CI: 0.89–0.95). …”
-
13203
Characteristics of the respondents (n = 2,151).
Published 2024“…After adjustment for other factors, it was found that higher age was associated with a decreased acceptance (AOR: 0.92; 95% CI: 0.89–0.95). …”
-
13204
Determinants of HPV vaccine acceptance.
Published 2024“…After adjustment for other factors, it was found that higher age was associated with a decreased acceptance (AOR: 0.92; 95% CI: 0.89–0.95). …”
-
13205
-
13206
-
13207
-
13208
Blood Pressure and LDL-C During Follow-up.
Published 2025“…The secondary endpoints were cardiovascular death, myocardial infarction, stroke, ischemic stroke, all-cause mortality, fracture, orthostatic hypotension, serious bleeding, and health-related quality of life. During a mean follow-up of 3.8 years, 31.7% (n = 64) of the patients in the intervention group and 37.5% (n = 72) in the control group reached the primary endpoint (HR 0.82, 95% CI 0.58–1.14, <i>P</i> = 0.23). …”
-
13209
Baseline Characteristics of Included Patients.
Published 2025“…The secondary endpoints were cardiovascular death, myocardial infarction, stroke, ischemic stroke, all-cause mortality, fracture, orthostatic hypotension, serious bleeding, and health-related quality of life. During a mean follow-up of 3.8 years, 31.7% (n = 64) of the patients in the intervention group and 37.5% (n = 72) in the control group reached the primary endpoint (HR 0.82, 95% CI 0.58–1.14, <i>P</i> = 0.23). …”
-
13210
Predictive validity.
Published 2023“…Quantitative score normalized to baseline (w = 100% in blue). <b>A) MLI-PC feed forward inhibition</b>. The change of total activity (measured as Area Under Curve (AUC)) and the initial peak amplitude decrease exponentially with the MLI-PC strength. …”
-
13211
-
13212
-
13213
-
13214
-
13215
-
13216
-
13217
-
13218
-
13219
-
13220